Oct. 20 at 12:54 PM
Abbott’s Q3: Earnings and Revenue Growth, But Why the Tepid Market Reaction? 🤔
Despite a solid Q3 with earnings in line with expectations and revenue miss,
$ABT's shares lagged behind rivals like Boston Scientific and Medtronic. Tariffs and concerns over ABT's stretched valuation compared to peers are capping enthusiasm. 📉
See the full breakdown here 👉 https://www.zacks.com/stock/news/2772221/abbott-q3-earnings-review-tariff-diagnostics-cap-near-term-gains?cid=sm-stocktwits-2-2772221-body-16760&ADID=SYND_STOCKTWITS_TWEET_2_2772221_BODY_16760